<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34803147</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>MRI at Restaging After Neoadjuvant Therapy for Rectal Cancer Overestimates Circumferential Resection Margin Proximity as Determined by Comparison With Whole-Mount Pathology.</ArticleTitle><Pagination><StartPage>489</StartPage><EndPage>496</EndPage><MedlinePgn>489-496</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002145</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Current guidelines recommend restaging with MRI after neoadjuvant therapy for rectal cancer, but the accuracy of restaging MRI in estimating circumferential margin involvement requires additional clarification.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this study was to measure the accuracy of circumferential resection margin assessment by MRI after neoadjuvant therapy and identify characteristics associated with accuracy.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">MRI data were retrospectively analyzed for concordance with the findings of whole-mount pathology analysis of the corresponding surgical specimens. Univariate and multivariate logistic regression analyses were performed to identify characteristics associated with accuracy.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">This study was conducted at a comprehensive cancer center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Included in the study were consecutive patients who underwent total mesorectal excision for rectal cancer between January 2018 and March 2020 after receiving neoadjuvant therapy and undergoing restaging with MRI.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The primary outcome of this study included accuracy, sensitivity, specificity, and positive and negative predictive values for categorizing the circumferential resection margin as threatened; mean and paired mean differences were in proximity of the margin.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 94 patients included in the analysis, 39 (41%) had a threatened circumferential resection margin according to MRI at restaging, but only 17 (18%) had a threatened margin based on pathology. The accuracy of MRI in identifying a threatened margin was 63.8%, with margin proximity overestimated by 0.4 cm on average. In multivariate logistic regression, anterior location of the margin and tumor proximity to the anal verge were independently associated with reduced MRI accuracy.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">A limitation was the retrospective design at a single institution.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The knowledge that MRI-based restaging after neoadjuvant therapy overestimates circumferential margin proximity may render some surgical radicality unnecessary and thereby help avoid the associated morbidity. With the recognition that MRI-based assessment of margin proximity may not be reliable for anterior margin and for distal tumors, radiologists may want to use greater caution in interpreting images of tumors with these characteristics and to acknowledge the uncertainty in their reports. See Video Abstract at http://links.lww.com/DCR/B814.</AbstractText><AbstractText Label="LA IRM EN LA REESTADIFICACIN LUEGO DE TERAPIA NEOADYUVANTE EN EL CNCER DE RECTO SOBRESTIMA LA PROXIMIDAD DEL MARGEN DE RESECCIN CIRCUNFERENCIAL SEGN LO DETERMINADO COMPARATIVAMENTE CON LA PIEZA DE ANATOMOPATOLOGA" NlmCategory="UNASSIGNED">ANTECEDENTES:Las pautas actuales recomiendan la re-estadificaci&#xf3;n por medio de la resonancia magn&#xe9;tica luego de terapia neoadyuvante en los casos de c&#xe1;ncer de recto, pero la precisi&#xf3;n de la reevaluaci&#xf3;n con la IRM para estimar el grado de implicaci&#xf3;n del margen circunferencial requiere aclaraciones adicionales.OBJETIVO:Medir el grado de exactitud en la evaluaci&#xf3;n del margen de resecci&#xf3;n circunferencial mediante resonancia magn&#xe9;tica despu&#xe9;s de la terapia neoadyuvante e identificar las caracter&#xed;sticas asociadas con la precisi&#xf3;n.DISE&#xd1;O:Se analizaron retrospectivamente los datos de resonancia magn&#xe9;tica para determinar la concordancia entre los hallazgos del an&#xe1;lisis de la pieza de anatamopatolog&#xed;a y las muestras quir&#xfa;rgicas correspondientes. Se realiz&#xf3; el an&#xe1;lisis de regresi&#xf3;n log&#xed;stica univariada y multivariada para identificar las caracter&#xed;sticas asociadas con la exactitud.AJUSTE:Centro oncol&#xf3;gico integral.PACIENTES:Todos aquellos que se sometieron consecutivamente a una excisi&#xf3;n total del mesorrecto por c&#xe1;ncer rectal entre Enero 2018 y Febrero 2020 luego de recibir terapia neoadyuvante y someterse a una re-estadificaci&#xf3;n por im&#xe1;genes de resonancia magn&#xe9;tica (IRM).PRINCIPALES MEDIDAS DE RESULTADO:La exactitud, la sensibilidad y especificidad; los valores predictivos positivos y negativos para categorizar el margen de resecci&#xf3;n circunferencial como amenazado; la diferencia media y las medias pareadas de proximidad a los margenes.RESULTADOS:De los 94 pacientes incluidos en el an&#xe1;lisis, 39 (41%) ten&#xed;an un margen de resecci&#xf3;n circunferencial amenazado seg&#xfa;n la resonancia magn&#xe9;tica en la re-estadificaci&#xf3;n, pero solo 17 (18%) ten&#xed;an un margen amenazado basado en la patolog&#xed;a. La precisi&#xf3;n de la resonancia magn&#xe9;tica para identificar un margen amenazado fue del 63,8%, con la proximidad del margen sobreestimada en 0,4&#x2009;cm en promedio. En la regresi&#xf3;n log&#xed;stica multivariada, la ubicaci&#xf3;n anterior de los bordes de resecci&#xf3;n y la proximidad del tumor al margen anal se asociaron de forma independiente con la reducci&#xf3;n en la precisi&#xf3;n de la resonancia magn&#xe9;tica.LIMITACIONES:Dise&#xf1;o retrospectivo en una instituci&#xf3;n &#xfa;nica.CONCLUSIONES:El saber que la re-estadificaci&#xf3;n basada en la IRM, luego de terapia neoadyuvante sobreestima la proximidad de la lesi&#xf3;n a los m&#xe1;rgenes circunferenciales, hace innecesaria cierta radicalidad quir&#xfa;rgica complementaria, lo que ayuda a evitar morbilidad asociada. Reconociendo que la evaluaci&#xf3;n de proximidad de los m&#xe1;rgenes de resecci&#xf3;n basada en la resonancia magn&#xe9;tica, no puede ser confiable en casos de m&#xe1;rgenes anteriores y en casos de tumores distales. Los radi&#xf3;logos recomiendan tener m&#xe1;s precauci&#xf3;n en la interpretaci&#xf3;n de im&#xe1;genes de tumores con estas caracter&#xed;sticas y reconocen cierto desasosiego en sus informes. Consulte Video Resumen en http://links.lww.com/DCR/B814.</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuval</LastName><ForeName>Jonathan B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Hannah M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Firat</LastName><ForeName>Canan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verheij</LastName><ForeName>Floris S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Widmar</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Iris H</ForeName><Initials>IH</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pappou</LastName><ForeName>Emmanouil</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>J Joshua</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiser</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paty</LastName><ForeName>Philip B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nash</LastName><ForeName>Garrett M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shia</LastName><ForeName>Jinru</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gollub</LastName><ForeName>Marc J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Aguilar</LastName><ForeName>Julio</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA009501</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072662" MajorTopicYN="Y">Margins of Excision</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="ANTECEDENTES:">Las pautas actuales recomiendan la re-estadificaci&#xf3;n por medio de la resonancia magn&#xe9;tica luego de terapia neoadyuvante en los casos de c&#xe1;ncer de recto, pero la precisi&#xf3;n de la reevaluaci&#xf3;n con la IRM para estimar el grado de implicaci&#xf3;n del margen circunferencial requiere aclaraciones adicionales.</AbstractText><AbstractText Label="OBJETIVO:">Medir el grado de exactitud en la evaluaci&#xf3;n del margen de resecci&#xf3;n circunferencial mediante resonancia magn&#xe9;tica despu&#xe9;s de la terapia neoadyuvante e identificar las caracter&#xed;sticas asociadas con la precisi&#xf3;n.</AbstractText><AbstractText Label="DISE&#xd1;O:">Se analizaron retrospectivamente los datos de resonancia magn&#xe9;tica para determinar la concordancia entre los hallazgos del an&#xe1;lisis de la pieza de anatamopatolog&#xed;a y las muestras quir&#xfa;rgicas correspondientes. Se realiz&#xf3; el an&#xe1;lisis de regresi&#xf3;n log&#xed;stica univariada y multivariada para identificar las caracter&#xed;sticas asociadas con la exactitud.</AbstractText><AbstractText Label="AJUSTE:">Centro oncol&#xf3;gico integral.</AbstractText><AbstractText Label="PACIENTES:">Todos aquellos que se sometieron consecutivamente a una excisi&#xf3;n total del mesorrecto por c&#xe1;ncer rectal entre Enero 2018 y Febrero 2020 luego de recibir terapia neoadyuvante y someterse a una re-estadificaci&#xf3;n por im&#xe1;genes de resonancia magn&#xe9;tica (IRM).</AbstractText><AbstractText Label="PRINCIPALES MEDIDAS DE RESULTADO:">La exactitud, la sensibilidad y especificidad; los valores predictivos positivos y negativos para categorizar el margen de resecci&#xf3;n circunferencial como amenazado; la diferencia media y las medias pareadas de proximidad a los margenes.</AbstractText><AbstractText Label="RESULTADOS:">De los 94 pacientes incluidos en el an&#xe1;lisis, 39 (41%) ten&#xed;an un margen de resecci&#xf3;n circunferencial amenazado seg&#xfa;n la resonancia magn&#xe9;tica en la re-estadificaci&#xf3;n, pero solo 17 (18%) ten&#xed;an un margen amenazado basado en la patolog&#xed;a. La precisi&#xf3;n de la resonancia magn&#xe9;tica para identificar un margen amenazado fue del 63,8%, con la proximidad del margen sobreestimada en 0,4 cm en promedio. En la regresi&#xf3;n log&#xed;stica multivariada, la ubicaci&#xf3;n anterior de los bordes de resecci&#xf3;n y la proximidad del tumor al margen anal se asociaron de forma independiente con la reducci&#xf3;n en la precisi&#xf3;n de la resonancia magn&#xe9;tica.</AbstractText><AbstractText Label="LIMITACIONES:">Dise&#xf1;o retrospectivo en una instituci&#xf3;n &#xfa;nica.</AbstractText><AbstractText Label="CONCLUSIONES:">El saber que la re-estadificaci&#xf3;n basada en la IRM, luego de terapia neoadyuvante sobreestima la proximidad de la lesi&#xf3;n a los m&#xe1;rgenes circunferenciales, hace innecesaria cierta radicalidad quir&#xfa;rgica complementaria, lo que ayuda a evitar morbilidad asociada. Reconociendo que la evaluaci&#xf3;n de proximidad de los m&#xe1;rgenes de resecci&#xf3;n basada en la resonancia magn&#xe9;tica, no puede ser confiable en casos de m&#xe1;rgenes anteriores y en casos de tumores distales. Los radi&#xf3;logos recomiendan tener m&#xe1;s precauci&#xf3;n en la interpretaci&#xf3;n de im&#xe1;genes de tumores con estas caracter&#xed;sticas y reconocen cierto desasosiego en sus informes. Consulte <b>Video Resumen</b> en https://links.lww.com/DCR/B814. <i>(Traducci&#xf3;n&#x2014;Dr. Xavier Delgadillo)</i></AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34803147</ArticleId><ArticleId IdType="mid">NIHMS1757586</ArticleId><ArticleId IdType="pmc">PMC8916980</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002145</ArticleId><ArticleId IdType="pii">00003453-202204000-00009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Birbeck KF, Macklin CP, Tiffin NJ, et al. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg. 2002;235:449&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1422458</ArticleId><ArticleId IdType="pubmed">11923599</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosens MJ, Klaassen RA, Tan-Go I, et al. Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res. 2007;13:6617&#x2013;6623.</Citation><ArticleIdList><ArticleId IdType="pubmed">18006762</ArticleId></ArticleIdList></Reference><Reference><Citation>Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet. 1986;2:996&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">2430152</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudyka V, Blomqvist L, Beets-Tan RG, et al. EURECCA consensus conference highlights about colon &amp; rectal cancer multidisciplinary management: the radiology experts review. Eur J Surg Oncol. 2014;40:469&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">24439446</ArticleId></ArticleIdList></Reference><Reference><Citation>Beets-Tan RGH, Lambregts DMJ, Maas M, et al. Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol. 2018;28:1465&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5834554</ArticleId><ArticleId IdType="pubmed">29043428</ArticleId></ArticleIdList></Reference><Reference><Citation>Beets-Tan RG, Beets GL, Vliegen RF, et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet. 2001;357:497&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">11229667</ArticleId></ArticleIdList></Reference><Reference><Citation>Nougaret S, Reinhold C, Mikhael HW, Rouanet P, Bibeau F, Brown G. The use of MR imaging in treatment planning for patients with rectal carcinoma: have you checked the &#x201c;DISTANCE&#x201d;? Radiology. 2013;268:330&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">23882096</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sande ME, Beets GL, Hupkens BJ, et al. Response assessment after (chemo)radiotherapy for rectal cancer: why are we missing complete responses with MRI and endoscopy? Eur J Surg Oncol. 2019;45:1011&#x2013;1017.</Citation><ArticleIdList><ArticleId IdType="pubmed">30528891</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni T, Gollins S, Maw A, Hobson P, Byrne R, Widdowson D. Magnetic resonance imaging in rectal cancer downstaged using neoadjuvant chemoradiation: accuracy of prediction of tumour stage and circumferential resection margin status. Colorectal Dis. 2008;10:479&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">18318754</ArticleId></ArticleIdList></Reference><Reference><Citation>Vliegen RF, Beets GL, Lammering G, et al. Mesorectal fascia invasion after neoadjuvant chemotherapy and radiation therapy for locally advanced rectal cancer: accuracy of MR imaging for prediction. Radiology. 2008;246:454&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">18227541</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbaro B, Fiorucci C, Tebala C, et al. Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy. Radiology. 2009;250:730&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">19244043</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim IY, Cha SW, Ahn JH, Kim YW. Factors affecting the restaging accuracy of magnetic resonance imaging after preoperative chemoradiation in patients with rectal cancer. Eur J Surg Oncol. 2015;41:493&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">25648465</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia X, Zhang Y, Wang Y, et al. MRI for restaging locally advanced rectal cancer: detailed analysis of discrepancies with the pathologic reference standard. AJR Am J Roentgenol. 2019;213:1081&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pubmed">31386575</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel UB, Taylor F, Blomqvist L, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011;29:3753&#x2013;3760.</Citation><ArticleIdList><ArticleId IdType="pubmed">21876084</ArticleId></ArticleIdList></Reference><Reference><Citation>Quirke P, Dixon MF. The prediction of local recurrence in rectal adenocarcinoma by histopathological examination. Int J Colorectal Dis. 1988;3:127&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">3045231</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Broek JJ, van der Wolf FS, Lahaye MJ, et al. Accuracy of MRI in restaging locally advanced rectal cancer after preoperative chemoradiation. Dis Colon Rectum. 2017;60:274&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">28177989</ArticleId></ArticleIdList></Reference><Reference><Citation>Patra A, Baheti AD, Ankathi SK, et al. Can post-treatment MRI features predict pathological circumferential resection margin (pCRM) involvement in low rectal tumors. Indian J Surg Oncol. 2020;11:720&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7714814</ArticleId><ArticleId IdType="pubmed">33281411</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Lee JM, Park HS, Eun HW, Han JK, Choi BI. Accuracy of MRI for predicting the circumferential resection margin, mesorectal fascia invasion, and tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. J Magn Reson Imaging. 2009;29:1093&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">19388124</ArticleId></ArticleIdList></Reference><Reference><Citation>McGlone ER, Shah V, Lowdell C, Blunt D, Cohen P, Dawson PM. Circumferential resection margins of rectal tumours post-radiotherapy: how can MRI aid surgical planning? Tech Coloproctol. 2014;18:937&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pubmed">25037073</ArticleId></ArticleIdList></Reference><Reference><Citation>Habr-Gama A, S&#xe3;o Juli&#xe3;o GP, Vailati BB, et al. Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy: the impact of radiation therapy dose-escalation and consolidation chemotherapy. Ann Surg. 2019;269:102&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">28742703</ArticleId></ArticleIdList></Reference><Reference><Citation>Peschaud F, Cuenod CA, Benoist S, et al. Accuracy of magnetic resonance imaging in rectal cancer depends on location of the tumor. Dis Colon Rectum. 2005;48:1603&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pubmed">15937629</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein NS, Soman A, Sacksner J. Disparate surgical margin lengths of colorectal resection specimens between in vivo and in vitro measurements. The effects of surgical resection and formalin fixation on organ shrinkage. Am J Clin Pathol. 1999;111:349&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">10078110</ArticleId></ArticleIdList></Reference><Reference><Citation>Oblizajek NR, Gandhi S, Sharma M, et al. Anorectal pressures measured with high-resolution manometry in healthy people-Normal values and asymptomatic pelvic floor dysfunction. Neurogastroenterol Motil. 2019;31:e13597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6559859</ArticleId><ArticleId IdType="pubmed">30957382</ArticleId></ArticleIdList></Reference><Reference><Citation>De Nardi P, Testoni SG, Corsetti M, et al. Manometric evaluation of anorectal function in patients treated with neoadjuvant chemoradiotherapy and total mesorectal excision for rectal cancer. Dig Liver Dis. 2017;49:91&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">27720700</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SH, Hu CY, Massarweh NN, et al. Circumferential resection margin as a hospital quality assessment tool for rectal cancer surgery. J Am Coll Surg. 2020;230:1008&#x2013;1018 e1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">32142927</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32032202</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Oncological Outcomes and Hospital Costs of the Treatment in Patients With Rectal Cancer: Watch-and-Wait Policy and Standard Surgical Treatment.</ArticleTitle><Pagination><StartPage>598</StartPage><EndPage>605</EndPage><MedlinePgn>598-605</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001594</ELocationID><Abstract><AbstractText Label="BACKGROUND">Little is known about the costs of the current treatment strategy in locally advanced rectal cancer, in which patients with a clinical complete response after chemoradiotherapy are treated in a watch-and-wait policy.</AbstractText><AbstractText Label="OBJECTIVE">The aim of this study is to present the oncological outcome and hospital costs of patients with a complete response after chemoradiotherapy (watch-and-wait policy) and patients with an incomplete response after chemoradiotherapy (total mesorectal excision).</AbstractText><AbstractText Label="DESIGN">This was a cohort study.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at an academic and a nonacademic hospital.</AbstractText><AbstractText Label="PATIENTS">Patients with locally advanced rectal cancer received either a watch-and-wait policy or total mesorectal excision depending on their clinical response to chemoradiotherapy.</AbstractText><AbstractText Label="INTERVENTIONS">Watch-and-wait policy and total mesorectal excision were the treatments applied.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcomes measured were overall, local recurrence-free, and distant metastasis-free survival and hospital costs over a 2-year follow-up period.</AbstractText><AbstractText Label="RESULTS">A total of 292 patients with locally advanced rectal cancer were included. Mean age was 65.1 years, and 64.7% were men. One hundred five patients were included in the watch-and-wait subgroup, and 187 patients were in the total mesorectal excision subgroup. Both subgroups showed good oncological outcomes. Hospital costs consisted of 5 categories: costs of primary surgery, costs of adjuvant chemotherapy, costs of examinations, costs of additional surgery, and costs of treatment of regrowth/metastasis. The mean costs per patient were &amp;OV0556;6713 (watch-and-wait subgroup) and &amp;OV0556;17,108 (total mesorectal excision subgroup) over the first 2 years.</AbstractText><AbstractText Label="LIMITATIONS">This study was limited by the following: costs were only from a hospital perspective, follow-up was 2 years, the study was retrospective in part, and there was no comparative study.</AbstractText><AbstractText Label="CONCLUSIONS">Overall survival was good in both subgroups and comparable to literature. The mean costs per patient differ between the watch-and-wait subgroup (&amp;OV0556;6713) and the total mesorectal excision subgroup (&amp;OV0556;17,108). No comparison between the groups could be made. Based on the results of this study, the current strategy, where patients with a clinical complete response are treated in a watch-and-wait policy, and patients with an incomplete response are treated with total mesorectal excision, is likely to be (cost)saving. See Video Abstract at http://links.lww.com/DCR/B177. RESULTADOS ONCOL&#xd3;GICOS Y COSTOS HOSPITALARIOS EN EL TRATAMIENTO DE PACIENTES CON CANCER DE RECTO: ACTITUD DE ESPERA-VIGILANCIA Y TRATAMIENTO QUIR&#xda;RGICO ESTANDARD: Se sabe poco sobre el costo del tratamiento actual en casos de cancer de recto localmente avanzado, cuando se aplica una pol&#xed;tica de vigilancia y espera en aquellos pacientes que presentan una respuesta cl&#xed;nica completa despu&#xe9;s de radio-quimioterapia.El prop&#xf3;sito final del presente estudio es dar a conocer el resultado oncol&#xf3;gico y los costos hospitalarios de los pacientes que presentan una respuesta cl&#xed;nica completa despu&#xe9;s de radio-quimioterapia (actitud de vigilancia-espera) y los pacientes con una respuesta incompleta despu&#xe9;s luego de radio-quimioterapia (excisi&#xf3;n total del mesorrecto-ETM).Estudio de cohortes.Hospitales acad&#xe9;micos y no acad&#xe9;micos.Todos aquellos pacientes tratados por un c&#xe1;ncer de recto localmente avanzado y que fueron seguidos con una pol&#xed;tica de vigilancia y espera o la ETM, en funci&#xf3;n de la respuesta cl&#xed;nica a la radio-quimioterapia.Pol&#xed;ticas de vigilancia-espera, excisi&#xf3;n total del mesorrecto.Sobrevida global libre de recurrencia local, met&#xe1;stasis a distancia, sobrevida libre de enfermedad y costos hospitalarios durante un per&#xed;odo de seguimiento de dos a&#xf1;os.Se incluyeron 292 pacientes diagnosticados de cancer de recto localmente avanzado. La edad media fue de 65,1 a&#xf1;os, 64,7% eran de sexo masculino. Se incluyeron 105 pacientes en el subgrupo de vigilancia-espera, y 187 en el subgrupo de excisi&#xf3;n total del mesorrecto. Ambos subgrupos mostraron optimos resultados oncol&#xf3;gicos. Los costos hospitalarios se dividieron en cinco categor&#xed;as: costos de cirug&#xed;a primaria; costos de quimioterapia adyuvante; costos de ex&#xe1;menes; costos de cirug&#xed;a adicional; y costos del tratamiento de rebrote / met&#xe1;stasis. Los costos medios por paciente fueron de &amp;OV0556; 6.713 (subgrupo de espera-vigilancia) y &amp;OV0556; 17.108 (subgrupo de excisi&#xf3;n total del mesorrecto) durante los primeros dos a&#xf1;os.Analisis de costos desde una perspectiva hospitalaria durante un seguimiento de dos a&#xf1;os, estudio parcialmente retrospectivo, no comparativo.La sobrevida general fue optima en ambos subgrupos y comparable con la literatura. El costo promedio por paciente difiere entre el subgrupo de vigilancia y espera (&amp;OV0556; 6.713) con el subgrupo de la ETM(&amp;OV0556; 17.108). No se pudieron comparar definitivamente ambos grupos. Basados en los resultados del presente estudio, es probable que la estrategia actual, en la que los pacientes con respuesta cl&#xed;nica completa sean tratados con una pol&#xed;tica de vigilancia y espera, presenten muy probablemente un cierto ahorro en el costo con relaci&#xf3;n a los pacientes con una respuesta incompleta tratados con excisi&#xf3;n total del mesorrecto. Consulte Video Resumen en http://links.lww.com/DCR/B177. (Traducci&#xf3;n-Dr. Xavier Delgadillo).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hupkens</LastName><ForeName>Britt J P</ForeName><Initials>BJP</Initials><AffiliationInfo><Affiliation>Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breukink</LastName><ForeName>St&#xe9;phanie O</ForeName><Initials>SO</Initials><AffiliationInfo><Affiliation>Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoot</LastName><ForeName>Jan H M B</ForeName><Initials>JHMB</Initials><AffiliationInfo><Affiliation>Department of Surgery, Zuyderland Medical Centre, Sittard-Heerlen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toebes</LastName><ForeName>Renee E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Sande</LastName><ForeName>Marit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melenhorst</LastName><ForeName>Jarno</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beets</LastName><ForeName>Geerard L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Department of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dirksen</LastName><ForeName>Carmen D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology and Medical Technology Assessment, Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017721" MajorTopicYN="Y">Hospital Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057832" MajorTopicYN="N">Watchful Waiting</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32032202</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001594</ArticleId><ArticleId IdType="pii">00003453-202005000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sauer R, Becker H, Hohenberger W, et al.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731&#x2013;1740.</Citation></Reference><Reference><Citation>Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835&#x2013;844.</Citation></Reference><Reference><Citation>Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918&#x2013;928.</Citation></Reference><Reference><Citation>Glynne-Jones R, Wallace M, Livingstone JI, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a &#x201c;wait and see&#x201d; policy justified? Dis Colon Rectum. 2008;51:10&#x2013;19.</Citation></Reference><Reference><Citation>Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711&#x2013;717.</Citation></Reference><Reference><Citation>Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29:4633&#x2013;4640.</Citation></Reference><Reference><Citation>Martens MH, Maas M, Heijnen LA, et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst. 2016;108:108&#x2013;120.</Citation></Reference><Reference><Citation>Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17:174&#x2013;183.</Citation></Reference><Reference><Citation>Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg. 2012;256:965&#x2013;972.</Citation></Reference><Reference><Citation>Gani C, Grosse U, Clasen S, et al. Cost analysis of a wait-and-see strategy after radiochemotherapy in distal rectal cancer. Strahlenther Onkol. 2018;194:985&#x2013;990.</Citation></Reference><Reference><Citation>Habr-Gama A, Lynn PB, Jorge JM, et al. Impact of organ-preserving strategies on anorectal function in patients with distal rectal cancer following neoadjuvant chemoradiation. Dis Colon Rectum. 2016;59:264&#x2013;269.</Citation></Reference><Reference><Citation>Hupkens BJP, Martens MH, Stoot JH, et al. Quality of life in rectal cancer patients after chemoradiation: watch-and-wait policy versus standard resection - a matched-controlled study. Dis Colon Rectum. 2017;60:1032&#x2013;1040.</Citation></Reference><Reference><Citation>Smith FM, Rao C, Oliva Perez R, et al. Avoiding radical surgery improves early survival in elderly patients with rectal cancer, demonstrating complete clinical response after neoadjuvant therapy: results of a decision-analytic model. Dis Colon Rectum. 2015;58:159&#x2013;171.</Citation></Reference><Reference><Citation>Rao C, Sun Myint A, Athanasiou T, et al. Avoiding radical surgery in elderly patients with rectal cancer is cost-effective. Dis Colon Rectum. 2017;60:30&#x2013;42.</Citation></Reference><Reference><Citation>Punt CJ, Buyse M, K&#xf6;hne CH, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst. 2007;99:998&#x2013;1003.</Citation></Reference><Reference><Citation>IJzerman MJ; Guideline for conducting economic evaluations in healthcare. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. 2016:1&#x2013;38.www.zorginstituutnederland.nl.</Citation></Reference><Reference><Citation>Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:501&#x2013;513.</Citation></Reference><Reference><Citation>van der Valk MJM, Hilling DE, Bastiaannet E, et al.; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch &amp; Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537&#x2013;2545.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>